Ubs Oconnor LLC Rain Therapeutics Inc. Transaction History

Ubs Oconnor LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$7.77 - $12.47 $1.81 Million - $2.91 Million	-233,114 Reduced 77.46%	67,842 $592,000
Q4 2022 Feb 14, 2023	SELL	$5.52 - $8.48 $140,732 - $216,197	-25,495 Reduced 7.81%	300,956 $0
Q3 2022 Nov 14, 2022	SELL	$4.75 - $8.01 $32,300 - $54,468	-6,800 Reduced 2.04%	326,451 $1.59 Billion
Q2 2022 Aug 12, 2022	BUY	$2.21 - $5.56 $541,408 - $1.36 Million	244,981 Added 277.54%	333,251 $1.85 Million
Q1 2022 May 16, 2022	BUY	$5.07 - $13.68 $447,528 - $1.21 Million	88,270 New	88,270 $447,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.